Ascendis Pharma A/S Announces Submission of Biologics License Application (BLA) to FDA for TransCon™ hGH in Pediatric Growth Hormone Deficiency


You May Also Like

TESARO to Announce Second-Quarter 2017 Financial Results on August 8, 2017

WALTHAM, Mass., July 25, 2017 (GLOBE NEWSWIRE) -- TESARO, Inc. (NASDAQ:TSRO) will announce its ...

UroGen Pharma Appoints Peter P. Pfreundschuh as Chief Financial Officer

Life Sciences Veteran Brings Extensive Global Finance, Commercial Operations and Business Development Experience to ...